10 January 2025
10 January 2025
Synaffix adds to the flurry of ADC dealmaking as it partners with Boehringer and Mitsubishi Tanabe with deals announced on the same day.
The partnership will leverage Samsung Biologics' new ADC facility equipped with a 500l reactor.
Under the agreement, Myung In Pharma is set to contribute 10% of the subjects to be enrolled for Newron's upcoming trial.
Novo Holdings and Bpifrance co-led the funding round.
Financing was co-led by Forbion and General Atlantic, with participants such as RA Capital Management, OrbiMed, and Lilly Asia Ventures.
The European Commission’s approval expansion follows the FDA’s same decision in July last year.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
